Cargando…

Spleen tyrosine kinase activity regulates epidermal growth factor receptor signaling pathway in ovarian cancer

BACKGROUND: Spleen tyrosine kinase (SYK) is frequently upregulated in recurrent ovarian carcinomas, for which effective therapy is urgently needed. SYK phosphorylates several substrates, but their translational implications remain unclear. Here, we show that SYK interacts with EGFR and ERBB2, and di...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Yu, Suryo Rahmanto, Yohan, Shen, Yao-An, Ardighieri, Laura, Davidson, Ben, Gaillard, Stephanie, Ayhan, Ayse, Shi, Xu, Xuan, Jianhua, Wang, Tian-Li, Shih, Ie-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6796592/
https://www.ncbi.nlm.nih.gov/pubmed/31492560
http://dx.doi.org/10.1016/j.ebiom.2019.08.055
_version_ 1783459640235786240
author Yu, Yu
Suryo Rahmanto, Yohan
Shen, Yao-An
Ardighieri, Laura
Davidson, Ben
Gaillard, Stephanie
Ayhan, Ayse
Shi, Xu
Xuan, Jianhua
Wang, Tian-Li
Shih, Ie-Ming
author_facet Yu, Yu
Suryo Rahmanto, Yohan
Shen, Yao-An
Ardighieri, Laura
Davidson, Ben
Gaillard, Stephanie
Ayhan, Ayse
Shi, Xu
Xuan, Jianhua
Wang, Tian-Li
Shih, Ie-Ming
author_sort Yu, Yu
collection PubMed
description BACKGROUND: Spleen tyrosine kinase (SYK) is frequently upregulated in recurrent ovarian carcinomas, for which effective therapy is urgently needed. SYK phosphorylates several substrates, but their translational implications remain unclear. Here, we show that SYK interacts with EGFR and ERBB2, and directly enhances their phosphorylation. METHODS: We used immunohistochemistry and immunoblotting to assess SYK and EGFR phosphorylation in ovarian serous carcinomas. Association with survival was determined by Kaplan-Meier analysis and the log-rank test. To study its role in EGFR signaling, SYK activity was modulated using a small molecule inhibitor, a syngeneic knockout, and an active kinase inducible system. We applied RNA-seq and phosphoproteomic mass spectrometry to investigate the SYK-regulated EGF-induced transcriptome and downstream substrates. FINDINGS: Induced expression of constitutively active SYK(130E) reduced cellular response to EGFR/ERBB2 inhibitor, lapatinib. Expression of EGFR(WT), but not SYK non-phosphorylatable EGFR(3F) mutant, resulted in paclitaxel resistance, a phenotype characteristic to SYK active ovarian cancers. In tumor xenografts, SYK inhibitor reduces phosphorylation of EGFR substrates. Compared to SYK(WT) cells, SYK(KO) cells have an attenuated EGFR/ERBB2-transcriptional activity and responsiveness to EGF-induced transcription. In ovarian cancer tissues, pSYK (Y525/526) levels showed a positive correlation with pEGFR (Y1187). Intense immunoreactivity of pSYK (Y525/526) correlated with poor overall survival in ovarian cancer patients. INTERPRETATION: These findings indicate that SYK activity positively modulates the EGFR pathway, providing a biological foundation for co-targeting SYK and EGFR. FUND: Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, NIH/NCI, Ovarian Cancer Research Foundation Alliance, HERA Women's Cancer Foundation and Roseman Foundation. Funders had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript and eventually in the decision to submit the manuscript.
format Online
Article
Text
id pubmed-6796592
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-67965922019-10-22 Spleen tyrosine kinase activity regulates epidermal growth factor receptor signaling pathway in ovarian cancer Yu, Yu Suryo Rahmanto, Yohan Shen, Yao-An Ardighieri, Laura Davidson, Ben Gaillard, Stephanie Ayhan, Ayse Shi, Xu Xuan, Jianhua Wang, Tian-Li Shih, Ie-Ming EBioMedicine Research paper BACKGROUND: Spleen tyrosine kinase (SYK) is frequently upregulated in recurrent ovarian carcinomas, for which effective therapy is urgently needed. SYK phosphorylates several substrates, but their translational implications remain unclear. Here, we show that SYK interacts with EGFR and ERBB2, and directly enhances their phosphorylation. METHODS: We used immunohistochemistry and immunoblotting to assess SYK and EGFR phosphorylation in ovarian serous carcinomas. Association with survival was determined by Kaplan-Meier analysis and the log-rank test. To study its role in EGFR signaling, SYK activity was modulated using a small molecule inhibitor, a syngeneic knockout, and an active kinase inducible system. We applied RNA-seq and phosphoproteomic mass spectrometry to investigate the SYK-regulated EGF-induced transcriptome and downstream substrates. FINDINGS: Induced expression of constitutively active SYK(130E) reduced cellular response to EGFR/ERBB2 inhibitor, lapatinib. Expression of EGFR(WT), but not SYK non-phosphorylatable EGFR(3F) mutant, resulted in paclitaxel resistance, a phenotype characteristic to SYK active ovarian cancers. In tumor xenografts, SYK inhibitor reduces phosphorylation of EGFR substrates. Compared to SYK(WT) cells, SYK(KO) cells have an attenuated EGFR/ERBB2-transcriptional activity and responsiveness to EGF-induced transcription. In ovarian cancer tissues, pSYK (Y525/526) levels showed a positive correlation with pEGFR (Y1187). Intense immunoreactivity of pSYK (Y525/526) correlated with poor overall survival in ovarian cancer patients. INTERPRETATION: These findings indicate that SYK activity positively modulates the EGFR pathway, providing a biological foundation for co-targeting SYK and EGFR. FUND: Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, NIH/NCI, Ovarian Cancer Research Foundation Alliance, HERA Women's Cancer Foundation and Roseman Foundation. Funders had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript and eventually in the decision to submit the manuscript. Elsevier 2019-09-03 /pmc/articles/PMC6796592/ /pubmed/31492560 http://dx.doi.org/10.1016/j.ebiom.2019.08.055 Text en Published by Elsevier B.V. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research paper
Yu, Yu
Suryo Rahmanto, Yohan
Shen, Yao-An
Ardighieri, Laura
Davidson, Ben
Gaillard, Stephanie
Ayhan, Ayse
Shi, Xu
Xuan, Jianhua
Wang, Tian-Li
Shih, Ie-Ming
Spleen tyrosine kinase activity regulates epidermal growth factor receptor signaling pathway in ovarian cancer
title Spleen tyrosine kinase activity regulates epidermal growth factor receptor signaling pathway in ovarian cancer
title_full Spleen tyrosine kinase activity regulates epidermal growth factor receptor signaling pathway in ovarian cancer
title_fullStr Spleen tyrosine kinase activity regulates epidermal growth factor receptor signaling pathway in ovarian cancer
title_full_unstemmed Spleen tyrosine kinase activity regulates epidermal growth factor receptor signaling pathway in ovarian cancer
title_short Spleen tyrosine kinase activity regulates epidermal growth factor receptor signaling pathway in ovarian cancer
title_sort spleen tyrosine kinase activity regulates epidermal growth factor receptor signaling pathway in ovarian cancer
topic Research paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6796592/
https://www.ncbi.nlm.nih.gov/pubmed/31492560
http://dx.doi.org/10.1016/j.ebiom.2019.08.055
work_keys_str_mv AT yuyu spleentyrosinekinaseactivityregulatesepidermalgrowthfactorreceptorsignalingpathwayinovariancancer
AT suryorahmantoyohan spleentyrosinekinaseactivityregulatesepidermalgrowthfactorreceptorsignalingpathwayinovariancancer
AT shenyaoan spleentyrosinekinaseactivityregulatesepidermalgrowthfactorreceptorsignalingpathwayinovariancancer
AT ardighierilaura spleentyrosinekinaseactivityregulatesepidermalgrowthfactorreceptorsignalingpathwayinovariancancer
AT davidsonben spleentyrosinekinaseactivityregulatesepidermalgrowthfactorreceptorsignalingpathwayinovariancancer
AT gaillardstephanie spleentyrosinekinaseactivityregulatesepidermalgrowthfactorreceptorsignalingpathwayinovariancancer
AT ayhanayse spleentyrosinekinaseactivityregulatesepidermalgrowthfactorreceptorsignalingpathwayinovariancancer
AT shixu spleentyrosinekinaseactivityregulatesepidermalgrowthfactorreceptorsignalingpathwayinovariancancer
AT xuanjianhua spleentyrosinekinaseactivityregulatesepidermalgrowthfactorreceptorsignalingpathwayinovariancancer
AT wangtianli spleentyrosinekinaseactivityregulatesepidermalgrowthfactorreceptorsignalingpathwayinovariancancer
AT shihieming spleentyrosinekinaseactivityregulatesepidermalgrowthfactorreceptorsignalingpathwayinovariancancer